Cardiometabolic Diseases Market Report 2026

Cardiometabolic Diseases Market Overview

• Cardiometabolic Diseases market size has reached to $115.27 billion in 2025 • Expected to grow to $143.73 billion in 2030 at a compound annual growth rate (CAGR) of 4.6% • Growth Driver: Rising Obesity Rates Fuel Growth In Cardiometabolic Disease Market • Market Trend: Cardiometabolic Diseases Market Embraces Advanced Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiometabolic Diseases Market?

Cardiometabolic diseases refer to a group of interconnected health conditions that impact both the cardiovascular and metabolic systems. These diseases often occur together and share common risk factors, such as obesity, physical inactivity, an unhealthy diet, and genetic predisposition. The main types of cardiometabolic diseases are chronic or congestive heart failure, hypertension, type 2 diabetes, and obesity. Congestive heart failure refers to a chronic condition in which the heart's ability to pump blood efficiently is compromised. The various treatments include ACE inhibitors, diuretics, glucophage, liposuction, and other treatments. The various dosages include tablets, injections, and various routes of administration including oral, intravenous, and others that are used by various end-users such as clinics, hospitals, and others.

What Is The Cardiometabolic Diseases Market Growth Forecast?

The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $143.73 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of digital health tools, expansion of early screening programs, growing focus on lifestyle-based interventions, increasing development of novel cardiometabolic drugs. Major trends in the forecast period include increasing focus on integrated disease management approaches, rising adoption of combination drug therapies, growing use of personalized treatment strategies, expansion of preventive cardiometabolic care models, enhanced emphasis on long-term disease monitoring.

Global Cardiometabolic Diseases Market Segmentation

1) By Type: Chronic Or Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity 2) By Treatment: ACE inhibitors, Diuretics, Glucophage 3) By Dosage: Tablet, Injection 4) By End-Users: Clinic, Hospital, Other End-Users Subsegments: 1) By Chronic Or Congestive Heart Failure: Systolic Heart Failure, Diastolic Heart Failure 2) By Hypertension: Primary Hypertension, Secondary Hypertension 3) By Type 2 Diabetes: Insulin Resistance, Impaired Glucose Tolerance 4) By Obesity: Class I Obesity (BMI 30-34.9), Class II Obesity (BMI 35-39.9), Class III Obesity (BMI 40 And above)

What Is The Driver Of The Cardiometabolic Diseases Market?

The rising prevalence of obesity is expected to propel the growth of the cardiometabolic disease market going forward. Obesity is a complex condition characterized by excessive body fat accumulation, leading to increased body weight and health complications. The prevalence of obesity is increasing as more people adopt sedentary lifestyles and high-calorie diets, which contribute to cardiovascular risk factors such as type 2 diabetes, hypertension, dyslipidemia, and sleep disorders. Cardiometabolic disease management addresses these risks by improving metabolic health and reducing complications associated with obesity. For instance, in May 2025, according to the Office for Health Improvement and Disparities (OHID), a UK-governmentagency, in 2023–2024, about 64.5% of adults (18+) in England were estimated to be either overweight or living with obesity, this is slightly up from 64.0% in the previous period (2022–2023). Therefore, the high rate of obesity is driving the growth of the cardiometabolic diseases industry.

Key Players In The Global Cardiometabolic Diseases Market

Major companies operating in the cardiometabolic diseases market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Edwards Lifesciences, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.

Global Cardiometabolic Diseases Market Trends and Insights

Major companies are operating in the cardiometabolic diseases market, focusing on adoption of advanced technologies such as cardiac disease detection platform launch to enhance early diagnosis and monitoring of cardiovascular conditions. Cardiac disease detection platform launch refers to the introduction of a specialized system designed to identify, monitor, and assess cardiovascular conditions using advanced diagnostic technologies, sensors, and data analytics, aiming to enable early detection, improve patient outcomes, and support clinical decision-making. For instance, in February 2023, Eko Health Inc., a US-based inventor of heart and lung disease-detecting digital health technologies, launched the Sensora cardiac disease detection platform. It includes artificial intelligence (AI) that reliably detects structural murmurs, a symptom of valvular heart disease (VHD), and care pathway analytics software that provides metrics and downstream insight into the patient journey through the healthcare system. This digital stethoscope is used to capture and analyze electrical impulses and heartbeats.

What Are Latest Mergers And Acquisitions In The Cardiometabolic Diseases Market?

In August 2023, Novo Nordisk, a Denmark-based healthcare company, acquired Embark Biotech for $498 million. This acquisition of Novo Nordisk aims to enhance its pipeline for treating obesity and other cardiometabolic diseases. Embark Biotech is a Denmark-based Biotech company, developed therapies for cardiometabolic conditions, including obesity and type 2 diabetes.

Regional Outlook

North America was the largest region in the cardiometabolic diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cardiometabolic Diseases Market?

The cardiometabolic diseases market consists of revenues earned by entities by providing services such as non-invasive CAD testing, cardio-preventive care, behavioral counseling, and clinical assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiometabolic diseases market also includes sales of medications, blood glucose monitoring devices, blood pressure monitors, cholesterol testing kits, and weight management products used to provide cardiometabolic diseases services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cardiometabolic Diseases Market Report 2026?

The cardiometabolic diseases market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cardiometabolic diseases industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.